JP2017528419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528419A5 JP2017528419A5 JP2016574944A JP2016574944A JP2017528419A5 JP 2017528419 A5 JP2017528419 A5 JP 2017528419A5 JP 2016574944 A JP2016574944 A JP 2016574944A JP 2016574944 A JP2016574944 A JP 2016574944A JP 2017528419 A5 JP2017528419 A5 JP 2017528419A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound according
- mic
- peptide linker
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 claims 8
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims 8
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 102000046181 human GDF15 Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14173664.5 | 2014-06-24 | ||
| EP14173664 | 2014-06-24 | ||
| PCT/EP2015/063596 WO2015197446A1 (en) | 2014-06-24 | 2015-06-17 | Mic-1 fusion proteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528419A JP2017528419A (ja) | 2017-09-28 |
| JP2017528419A5 true JP2017528419A5 (enExample) | 2018-07-12 |
| JP6696915B2 JP6696915B2 (ja) | 2020-05-20 |
Family
ID=51032955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574944A Expired - Fee Related JP6696915B2 (ja) | 2014-06-24 | 2015-06-17 | Ｍｉｃ−１融合タンパク質及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9272019B2 (enExample) |
| EP (1) | EP3160496B1 (enExample) |
| JP (1) | JP6696915B2 (enExample) |
| KR (1) | KR20170020383A (enExample) |
| CN (1) | CN106459222A (enExample) |
| AR (1) | AR100945A1 (enExample) |
| AU (1) | AU2015279525A1 (enExample) |
| BR (1) | BR112016029848A2 (enExample) |
| CA (1) | CA2952293A1 (enExample) |
| IL (1) | IL249327A0 (enExample) |
| MX (1) | MX2016016063A (enExample) |
| RU (1) | RU2017101436A (enExample) |
| TW (1) | TW201613958A (enExample) |
| WO (1) | WO2015197446A1 (enExample) |
| ZA (1) | ZA201608214B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| EP3027642B1 (en) | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| PE20190117A1 (es) * | 2016-05-24 | 2019-01-16 | Novo Nordisk As | Compuestos de mic-1 y usos de estos |
| GB201615844D0 (en) * | 2016-09-16 | 2016-11-02 | Genagon Therapeutics Ab | Agents for use in therapy |
| EP3551214B1 (en) * | 2016-12-06 | 2024-03-13 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700553D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| CN110770251A (zh) * | 2017-04-20 | 2020-02-07 | 诺和诺德股份有限公司 | 纯化白蛋白融合蛋白的方法 |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| US11260108B2 (en) | 2017-09-10 | 2022-03-01 | Novo Nordisk A/S | MIC-1 and GLP-1 for use in the treatment of obesity |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| MA52205A (fr) | 2018-04-09 | 2021-02-17 | Amgen Inc | Protéines de fusion du facteur de différenciation de croissance 15 |
| AU2019317813A1 (en) | 2018-08-10 | 2021-02-11 | Novartis Ag | GFRAL extracellular domains and methods of use |
| EP3833377B1 (en) | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Bone healing at implants using alkaline phosphatase |
| CN119751697A (zh) | 2018-10-22 | 2025-04-04 | 詹森药业有限公司 | 胰高血糖素样肽1（glp1）-生长分化因子15（gdf15）融合蛋白及其用途 |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| CN114729020A (zh) * | 2019-11-26 | 2022-07-08 | 株式会社柳韩洋行 | 长效gdf15融合蛋白及包含其的药物组合物 |
| US12433938B2 (en) * | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| JP7655619B2 (ja) * | 2019-12-11 | 2025-04-02 | エルジー・ケム・リミテッド | Ｏ－グリコシル化可能なポリペプチド領域およびｇｄｆ１５を含む融合ポリペプチド |
| US12358963B2 (en) * | 2019-12-24 | 2025-07-15 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2021194257A1 (ko) * | 2020-03-25 | 2021-09-30 | (주) 업테라 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| KR102195740B1 (ko) * | 2020-03-25 | 2020-12-28 | 서울대학교산학협력단 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| CN115244076B (zh) | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| CN112694520B (zh) * | 2020-12-02 | 2023-01-17 | 图凌(杭州)生物医药有限公司 | 一种人工多肽hm、其抗体及在病理检测中的应用 |
| KR20230145120A (ko) | 2021-02-12 | 2023-10-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| ES2332100T3 (es) * | 2004-05-13 | 2010-01-26 | Eli Lilly And Company | Proteinas de fusion del fgf-21. |
| AU2005266184A1 (en) * | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| EP3027642B1 (en) | 2013-07-31 | 2020-08-19 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
-
2015
- 2015-06-17 CA CA2952293A patent/CA2952293A1/en not_active Withdrawn
- 2015-06-17 RU RU2017101436A patent/RU2017101436A/ru unknown
- 2015-06-17 CN CN201580033507.XA patent/CN106459222A/zh not_active Withdrawn
- 2015-06-17 TW TW104119532A patent/TW201613958A/zh unknown
- 2015-06-17 EP EP15730140.9A patent/EP3160496B1/en not_active Withdrawn - After Issue
- 2015-06-17 KR KR1020167037059A patent/KR20170020383A/ko not_active Withdrawn
- 2015-06-17 BR BR112016029848A patent/BR112016029848A2/pt not_active Application Discontinuation
- 2015-06-17 MX MX2016016063A patent/MX2016016063A/es unknown
- 2015-06-17 US US14/742,159 patent/US9272019B2/en not_active Expired - Fee Related
- 2015-06-17 WO PCT/EP2015/063596 patent/WO2015197446A1/en not_active Ceased
- 2015-06-17 JP JP2016574944A patent/JP6696915B2/ja not_active Expired - Fee Related
- 2015-06-17 AU AU2015279525A patent/AU2015279525A1/en not_active Withdrawn
- 2015-06-23 AR ARP150102007A patent/AR100945A1/es active IP Right Grant
-
2016
- 2016-01-19 US US15/000,637 patent/US9956264B2/en not_active Expired - Fee Related
- 2016-11-28 ZA ZA2016/08214A patent/ZA201608214B/en unknown
- 2016-12-01 IL IL249327A patent/IL249327A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528419A5 (enExample) | ||
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2016512213A5 (enExample) | ||
| HRP20200503T1 (hr) | Fuzijski proteini | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| JP2018503668A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| HRP20231437T1 (hr) | Il-15 i il-15ralpha sushi domena na temelju modulokina | |
| JP2017513503A5 (enExample) | ||
| WO2015188132A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
| JP2019533722A5 (enExample) | ||
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| JP2014525901A5 (enExample) | ||
| JP2016510728A5 (enExample) | ||
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| JP2018505146A5 (enExample) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| TW201119668A (en) | Peptidic GLP-2 agonists | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE |